Moncef Slaoui speaks with President Donald Trump about Operation Warp Speed in the Rose Garden of the White House on Friday November 13, 2020 in Washington, DC.
Jabin Botsford | The Washington Post | Getty Images
Moncef Slaoui, chief scientist for the US government’s Covid vaccine development, Operation Warp Speed, during the Trump administration, was fired from Galvani Bioelectronics’s board of directors on Wednesday for “substantiated” sexual harassment charges against a woman.
Slaoui’s termination by the board of directors of Galvani majority shareholder GlaxoSmithKline came after GSK was sent a letter in February entitled “Allegations of sexual harassment and inappropriate behavior by Dr. Slaoui against a GSK employee,” GSK said in a statement.
This behavior “occurred a few years ago when he was a GSK employee,” the statement said.
61-year-old Slaoui had spent 30 years at GSK overseeing vaccine development at this pharmaceutical giant.
“Upon receiving the letter, the GSK board immediately opened an investigation with an experienced law firm to investigate the allegations,” said GSK.
“The investigation into Dr. Slaoui’s behavior has substantiated the allegations and is ongoing.”
“Dr. Slaoui’s behavior is completely unacceptable,” said GSK.
Galvani Bioelectronics is a medical research company focused on developing bioelectronic drugs for the treatment of chronic diseases. It was formed through a partnership between GSK and Verily Life Sciences, previously known as Google Life Sciences. Verily, it is a subsidiary of Alphabet, the parent company of Google.
Slaoui’s discharge came 10 months after then-President Donald Trump tapped him to oversee U.S. efforts to develop vaccines to fight the coronavirus pandemic.
Moncef Slaoui, a former executive director of GlaxoSmithKline, speaks to President Donald J. Trump during a vaccine development event in the White House Rose Garden on Friday, May 15, 2020 in Washington, DC.
Jabin Botsford | The Washington Post | Getty Images
He is married to Kristen Slaoui, who previously served as Vice President and Head of Business Development at GSK.
Emma Walmsley, CEO of GSK, revealed in a letter to the staff Slaoui’s dismissal, saying, “Personally, I am shocked and angry about all of this, but I am determined.”
“I want to make it clear that sexual harassment is strictly prohibited and will not be tolerated,” wrote Walmsley.
She also wrote that GSK will be removing and renaming Slaoui’s name from its research and development center in Rockville, Maryland. It was called the Slaoui Center for Vaccine Research.
Walmsley also wrote that she chose to “write openly to everyone because these subjects are fundamental to me”.
“Since February, the highest levels of our company have been working to understand and address what happened,” wrote the CEO.
“The protection of the woman who came forward and her privacy has been a major priority during this time. This will continue,” wrote Walmsley. “I respect and admire their courage and strength. I’ve spent many nights lately putting myself in their shoes. More than anything, this simply shouldn’t have happened.”
Walmsley asked GSK employees to notify the company “if you have anything to say about this situation, a situation you were in personally or were familiar with.”
In its public statement, GSK said that Slaoui’s actions “constitute an abuse of his leadership position, violate company policies and contradict the strong values that define GSK’s culture”.
“The company expects everyone at GSK to behave according to their values, especially their executives, who have the highest standards. Sexual harassment and abuse of leadership positions are strictly prohibited and will not be tolerated.”
Slaoui advised the European Union on the introduction of coronavirus vaccines. CNBC had reached out to the EU for comment.
Slaoui submitted his resignation as Chief Advisor to Operation Warp Speed to the then-incoming administration of President Joe Biden in January.
He was criticized for taking on the OWS role for being associated with the pharmaceutical industry.
At the time of his appointment, he was on the board of Moderna. Slaoui resigned from Moderna and also sold his shares in that company. He said he donated her appreciation during the days he held her during Operation Warp Speed.
But he had refused to sell his GSK stock, calling it his retirement plan.
GSK announced on Wednesday that Christopher Corsico, GSK’s senior vice president of development and current board member of Galvani, has been named Galvani’s new chairman.
GSK also said that Amy Altshul, senior vice president of legal, research and development, and global commercial franchises, has joined Galvani’s board of directors.